RT Journal Article
SR Electronic
T1 N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.24.21264020
DO 10.1101/2021.09.24.21264020
A1 Kyriakos Martakis
A1 Jens Claassen
A1 Jordi Gascon-Bayarri
A1 Nicolina Goldschagg
A1 Andreas Hahn
A1 Anhar Hassan
A1 Anita Hennig
A1 Simon A. Jones
A1 Heather Lau
A1 Susan Perlman
A1 Reena Sharma
A1 Susanne A. Schneider
A1 Tatiana Bremova-Ertl
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264020.abstract
AB Background and Objective GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are rare, inherited neurodegenerative disorders with no available symptomatic or disease modifying treatments. This clinical trial aimed to investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms of pediatric (≥ 6 years) and adult patients with GM2 gangliosidosis.Methods \We conducted an 8-center, multi-national, open-label, rater-blinded Phase IIb study (IB1001-201). Patients with a genetically confirmed diagnosis of GM2 gangliosidosis were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥13 years, weight-tiered doses for patients 6-12 years), and a 6-week post-treatment washout period. The primary Clinical Impression of Change in Severity (CI-CS) endpoint (based on a 7-point Likert scale) was assessed by blinded, centralized raters who compared randomized video pairs of each patient performing a pre-defined primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) during each study periods. Secondary outcomes included cerebellar rating scales (namely Scale for the Assessment and Rating of Ataxia), clinical global impression, and quality of life assessments.Results 30 patients aged 6 to 55 years with a confirmed diagnosis of GM2 gangliosidosis (Tay-Sachs or Sandhoff’s disease) were enrolled. 29 patients were included in the primary modified intention-to-treat analysis. NALL met the CI-CS primary endpoint (mean difference 0.71, SD=2.09, 90% CI 0.00, 1.50, p=0.044), as well as secondary endpoints. No treatment-related serious adverse events occurred.Conclusions This study showed NALL led to a statistically significant improvement in symptoms, functioning, and quality of life in patients with GM2 gangliosidosis. It is a safe, well-tolerated, easily administered oral therapy, therefore offering a favorable risk/benefit profile for this serious, debilitating disorder. NALL is a new therapeutic option for the treatment of this rare disease that has no other approved therapies worldwide.Classification of Evidence This study provides Class IV evidence NALL is safe, well-tolerated, and improves neurological symptoms and quality of life in patients with GM2 gangliosidosis.Trial Registration Information The trial is registered with ClinicalTrials.gov (NCT03759665; registered 30-Nov-2018), EudraCT (2018-004406-25), and DRKS (DRKS00017539). The first patient was enrolled 07-June-2019.Competing Interest StatementT. Bremova-Ertl, J. Claassen and N. Goldschagg received fees for the blinded rater services from IntraBio. All other authors declare no competing interests. All other authors report no disclosures relevant to the manuscript.Clinical TrialNCT03759665Funding StatementThe study was funded by IntraBio Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study (clinicaltrials.gov identifier NCT03759639, EudraCT number 2018004331-71, and DR KS-ID: DRKS00016567) was obtained by National Regulatory Authorities in each country (German Federal Institute for Drugs and Medical Devices, Spain Agency of Medicines and Medical Devices, UK Medicines and Healthcare products Regulatory Agency, and US Food and Drug Administration), and the applicable responsible central research ethics committees / institutional review boards for each center (Ethics Committee of Ludwig Maximilian University of Munich (19-119), Bellvitge Hospital University Clinical Research Ethics Committee (AC004/19), North West - Greater Manchester South (260774) Mayo Clinic Institutional Review Board (19-000373), Office of Science and Research Institutional Review Board, New York University School of Medicine (i17-01666), University of California Los Angeles Institutional Review Board (19-000348)). Written informed consent was obtained for all study participants by the patient or, if applicable, their parent or legal representative.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study Sponsor, IntraBio Ltd. is committed to providing qualified scientific researchers appropriate access to anonymized data and clinical study information from the company's clinical trials for the purpose of conducting legitimate scientific research. Requests for specific data will be considered along with the rationale, description of use need, and clinical value of the proposed analysis. IntraBio supports an approach to sharing data that responsibly reflects the interests of all parties involved in clinical trials, including protecting the rights and privacy of trial participants, the innovator's intellectual property rights, and other incentives for innovation, and as such, will evaluate requests for sharing company clinical trial data with qualified external scientific researchers. Requests to access the data from this clinical trial may be made at info{at}intrabio.com. Data will be made available for request after product approval in the United States and European Union, after product development is discontinued, or as otherwise required by law or regulation. There are circumstances that may prevent IntraBio from sharing the requested data as the product is investigational at this time.